Sight Sciences, Inc. (SGHT) earnings date
Mar 10, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 45% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-20
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 38 days, typically, give or take 12 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | after close | 35 | 8-K |
| Q2 FY2026 | Wed, Aug 5, 2026 | after close | 36 | 8-K |
| Q1 FY2026 | Wed, May 6, 2026 | after close | 36 | 8-K |
| Q4 FY2025 | Wed, Mar 4, 2026 | after close | 63 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | after close | 38 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | after close | 38 | 8-K |
| Q4 FY2024 | Wed, Mar 5, 2025 | after close | 64 | 8-K |
What they guided beta
| Q3 FY2026 | "Exhibit 99.1 Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance MENLO PARK, Calif., November 4, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the third quarter ended September 30, 2026." exhibit |
| Q3 FY2026 | "2026 Financial Guidance Sight Sciences raised its revenue guidance for full year 2026 to range from $92 million to $93 million, representing year-over-year growth of 19% to 20%, versus prior revenue guidance of $88 million to $92 million." exhibit Read from the sentence: revenue $92 million to $93 million, FY2026 |
| Q3 FY2026 | "This revenue guidance includes Interventional Glaucoma revenue of $80 million to $81 million, representing growth of 6% to 7%, and Interventional Dry Eye revenue of approximately $12 million, compared to the previous range of $9 million to $11 million and compared to $1.6 million in 2025." exhibit |
| Q3 FY2026 | "The Company maintained its full year 2026 adjusted operating expenses 1,3 guidance to range from $92 million to $94 million, representing an increase of 5% to 7% compared to 2025. 1 “ Adjusted operating expenses” is a financial measure not prepared in accordance with generally accepted accounting principles in the United States (“GAAP”, and is referred to as a “non-GAAP financial measure”)." exhibit |
| Q2 FY2026 | "Exhibit 99.1 Sight Sciences Reports Second Quarter 2026 Financial Results Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance MENLO PARK, Calif., August 5, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today reported financial results for the second quarter ended June 30, 2026, raised its revenue guidance and reduced its adjusted operating expen" exhibit |
| Q2 FY2026 | "year-to-date performance and business momentum, we are raising our 2026 revenue guidance, reducing our adjusted operating expense guidance and we believe we are well positioned for the second half of the year.”" exhibit |
| Q2 FY2026 | "Total operating expenses were $25.3 million in the second quarter of 2026, representing an 11% decrease compared to $28.3 million in the same period in the prior year, primarily due to lower personnel-related expenses and stock-based compensation." exhibit |
| Q2 FY2026 | "Cash used in the second quarter of 2026 totaled $5.2 million, a 28% decrease compared to $7.3 million in the second quarter of 2025 . 2026 Financial Guidance Sight Sciences raised its revenue guidance for full year 2026 to range from $88 million to $92 million, representing year-over-year growth of 14% to 19%, versus prior revenue guidance of $83 million to $89 million." exhibit Read from the sentence: revenue $88 million to $92 million, FY2026 |
| Q2 FY2026 | "This revenue guidance includes Interventional Glaucoma revenue of $79 million to $81 million, representing growth of 4% to 7%, and Interventional Dry Eye revenue of $9 million to $11 million, compared to $1.6 million in 2025." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SGHT
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SGHT
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/SGHT/"><img src="https://veritasdata.dev/embed/SGHT.svg" alt="SGHT earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/SGHT/)
Script
<script async src="https://veritasdata.dev/embed/SGHT.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SGHT"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.